Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Boehringer gets US FDA...

    Boehringer gets US FDA nod for type 2 diabetes drug

    Written by supriya kashyap kashyap Published On 2016-12-09T10:19:52+05:30  |  Updated On 9 Dec 2016 10:19 AM IST
    Boehringer gets US FDA nod for type 2 diabetes drug

    Mumbai : Pharma firm Boehringer Ingelheim said it has got approval from the US health regulator for a new indication for Jardiance (empagliflozin) tablets, used to reduce the risk of cardiovascular death in adults with type 2 diabetes.


    In a statement here, the company said, "We have received the US Food and Drug Administration (FDA) approval for a new indication for Jardiance (empagliflozin) tablets, used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease."


    Jardiance, marketed by Boehringer, is the first type 2 diabetes treatment approved with this additional indication and the only oral type 2 medicine shown in a clinical trial to provide a life-saving cardiovascular benefit.


    Jardiance is not for people with type 1 diabetes or those with diabetic ketoacidosis (increased ketones in the blood or urine), the statement said.


    "As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, Jardiance represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with type 2 diabetes and cardiovascular disease," Boehringer Head of Therapeutic Area CardioMetabolism Georg van Husen Said.


    "This approval is another example of our commitment to the discovery and development of treatment options for adults with type 2 diabetes," he said.


    "Globally, the prevalence of type 2 diabetes is high and is reaching alarming proportions in many countries, especially India. With the FDA approval, Jardiance is a proven option for reducing cardiovascular mortality in adult patients of type-2 diabetes, having cardiovascular disease.


    "This breakthrough approval from the US FDA shows our commitment towards providing novel and innovative treatment options for diabetes management," Boehringer India Managing Director Sharad Tyagi said.


    In 2014, Jardiance was approved by the US FDA as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes. In India, Jardiance is currently approved for use an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

    Boehringer Ingelheimcardiovascular deathdiabetesdiabetes drugJardianceSharad Tyagitype 2 diabetes drugtype-2 diabetesUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok